Need to keep on high of the science and politics driving biotech right this moment? Join to get our biotech publication in your inbox.
Good morning. From DC to Boston to Utah, we’ve received information from throughout right this moment.
The necessity-to-know this morning
BridgeBio stated the FDA granted precedence assessment to its oral remedy for youngsters with achondroplasia, a typical type of dwarfism. An approval choice on the drug, known as infigratinib, is anticipated by Feb. 4, 2027.
Japan’s Shionogi has acquired for $2 billion the U.S.-based biotech IntraBio, the maker of an authorised drug that treats the neurological signs of two uncommon illnesses.
Arrivent Biopharma stated its experimental remedy for exon 20-mutated lung most cancers didn’t delay tumor development in a Section 3 research.
Trump admin says drug worth disclosures are coming
Trump administration officers stated yesterday they will begin creating a system for well being insurers to reveal prescription drug costs, and a “hopeful” closing plan will come out by subsequent Could.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
